Biomea Fusion, Inc. BMEA
Set alert
As of Nov 2, 10:47 AM ET
- YTD
- -49.82%
- 1 year
- -54.25%
- Open
- 0.636
- Prev close
- 0.6395
- Mkt cap
- 45.19M
- Vol
- 157.13K
- Avg vol
- 2.13M
- EPS
- -0.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.6234
- High
- 0.66
- Forward P/E
- -1.21
- Beta
- -0.43
- Short ratio
- 12.98
- Inst. own
- 64.56%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 31, 2024
- 50-d avg
- 7.91
- 200-d avg
- 8.85
- 1y target
- 40.56
6M chart
Signals (24)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| RSI: Overbought | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Jul 22, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 30, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 6 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
News
2 weeks ago defenseworld.net
Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
Biomea Fusion (NASDAQ: BMEA) reported top-line results from a Phase Ib multiple ascending-dose study of BMF-650, an investigational oral small-molecule GLP-1 receptor agonist being developed for…
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers MaxCyte (NASDAQ:MXCT) shares rose 34.5% to $1.3 during Wednesday's regular session. The company's market cap stands at $102.6 million. Liquidia (NASDAQ:LQDA) stock moved upwards by 26.29% to…
-
2 weeks ago benzinga.com
Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target
Citizens analyst Jonathan Wolleben reiterates Biomea Fusion (NASDAQ:BMEA) with a Market Outperform and maintains $7 price target.
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Liquidia (NASDAQ:LQDA) shares moved upwards by 41.0% to $37.8 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.4 billion. Greenland Mines…
2 weeks ago benzinga.com
State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. futures were mixed. State Street fell 6.4% after missing sales estimates, while Biomea Fusion, Skydance and other stocks slid premarket.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $4 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $4 price target.
2 weeks ago benzinga.com
Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.
2 weeks ago benzinga.com
What’s Going On With Biomea Fusion (BMEA) Stock After Hours?
Biomea Fusion reports Phase 1 BMF-650 results, with weight reduction and safety data from its oral GLP-1 drug trial.
2 weeks ago marketbeat.com
Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
Biomea Fusion NASDAQ: BMEA reported top-line results from a Phase Ib multiple ascending-dose study of BMF-650, an investigational oral small-molecule GLP-1 receptor agonist being developed for weight…
2 weeks ago seekingalpha.com
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript
-
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 20.5% to $3.65 during Tuesday's after-market session. The market value of their outstanding shares is at $2.6 million. Circle8 Group…
-
2 weeks ago benzinga.com
Biomea Fusion BMF-650 Phase 1 Weight Loss Results Remain Preliminary, With Longer-Term Trials And Toxicology Studies Still Outstanding
Safety and TolerabilityAcross the five active-dose MAD cohorts (n=40), all reported treatment-emergent adverse events (TEAEs) were mild or moderate. There were no severe or serious TEAEs,…
-
2 weeks ago benzinga.com
Biomea Fusion Reports Phase 1 Results For Oral GLP-1 Candidate BMF-650, Showing Consistent Weight Reduction And Encouraging Tolerability
Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related…
2 weeks ago globenewswire.com
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
SAN CARLOS, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced Phase 1 GLP-131…
2 weeks ago benzinga.com
Biomea Fusion Stock Climbs 7% After-Hours: What's Going On?
Biomea Fusion shares rise after-hours before Phase I results for oral GLP-1 candidate BMF-650.
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
-
2 weeks ago benzinga.com
Biomea Fusion To Report Results From Phase I GLP-131 Clinical Study Evaluating BMF-650, Investigational Next-Gen Oral Small-Molecule GLP-1 Receptor Agonist, On October 13
Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company, today announced that it will report results from its Phase I GLP-131 clinical study…
2 weeks ago globenewswire.com
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
-
3 weeks ago benzinga.com
Brookline Capital Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $10
Brookline Capital analyst Kumaraguru Raja initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Buy rating and announces Price Target of $10.
1 month ago benzinga.com
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data
Biomea Fusion, Inc. (NASDAQ:BMEA) shares are trading lower by almost 19% on Wednesday as investors digest the company's decision to terminate its proposed public offering.
1 month ago benzinga.com
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data
Biomea Fusion stock falls after ending a public securities offering and revising clinical data timelines for its obesity trial.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics…
-
1 month ago benzinga.com
Biomea Fusion Terminates Proposed Public Offering Of Securities Due To Market Conditions
Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities,…
1 month ago globenewswire.com
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has…
1 month ago benzinga.com
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.
1 month ago benzinga.com
Biomea Fusion Shares Fall 19% After Hours: Here’s Why
Biomea Fusion shares fall nearly 19% after hours, highlighting volatility in BMEA after Tuesday's session.
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG)…
1 month ago globenewswire.com
Biomea Fusion Announces Proposed Public Offering of Securities
SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an…
1 month ago zacks.com
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
Biomea Fusion, Inc. (BMEA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BMEA's 50-day simple moving average crossed above…
2 months ago globenewswire.com
Biomea Fusion to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today…
2 months ago benzinga.com
Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
Shares of Biomea Fusion Inc (NASDAQ:BMEA) are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.
2 months ago benzinga.com
Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
Shares of Biomea Fusion are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular session. The market value of their outstanding shares is at $5.8 million. Picard Medical (AMEX:PMI) shares…
2 months ago globenewswire.com
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
SAN CARLOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today…
2 months ago invezz.com
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying…
2 months ago globenewswire.com
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes
-
2 months ago benzinga.com
Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 76.47 percent increase over losses of…
2 months ago globenewswire.com
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
SAN CARLOS, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported…
-
4 months ago benzinga.com
Reported Friday, Biomea Fusion Presents ADA Data Showing Icovamenib Delivers 1.8% Placebo-Adjusted HbA1c Reduction In T2D Patients On Background GLP-1 Therapy
Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including…
4 months ago globenewswire.com
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including…
-
5 months ago benzinga.com
Biomea Fusion Partners With The University Of Leicester For Ongoing Platform Research Study Titled 'Investigating And Optimizing Physical Function With Weight Loss: A Multi-Arm Open Label Adaptive Platform Trial'
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic OutcomesLate-Breaking…
5 months ago globenewswire.com
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking…
5 months ago globenewswire.com
Biomea Fusion to Participate at Upcoming Investor Conferences
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management…
-
5 months ago benzinga.com
Biomea Fusion Q1 EPS $(0.17) Beats $(0.24) Estimate
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.24) by 29.17 percent. This is a 78.75 percent increase over losses of…
5 months ago globenewswire.com
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported…
6 months ago benzinga.com
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Citations for AMAT, BMEA, ACRS, KALU, SION.
-
6 months ago benzinga.com
Citizens Initiates Coverage On Biomea Fusion with Market Outperform Rating, Announces Price Target of $9
Citizens analyst Jonathan Wolleben initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Market Outperform rating and announces Price Target of $9.
-
6 months ago benzinga.com
Biomea Fusion Reveals 52-Week Results From Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment; In Patients Diagnosed Within 0-3 Years, Treatment With Icovamenib 200 Mg Once Daily For 12 Weeks Resulted In A 52% Increase In Mean C-peptide Area Under The Curve At Week 12
A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence…
-
7 months ago benzinga.com
Biomea Fusion Starts New Trials to Test Diabetes Drug in Patients
Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the first patient has been dosed in its…
-
7 months ago benzinga.com
Citigroup Maintains Buy on Biomea Fusion, Raises Price Target to $7
Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and raises the price target from $6 to $7.